Our End-of-Phase 2 meeting with FDA was productive and provided Lexicon with the insights needed to design a robust Phase 3 program, with the goal of making the first non-opioid DPNP medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback